Genflow Biosciences Investors - GENF

Genflow Biosciences Investors - GENF

Buy
Sell
Stock Name Stock Symbol Market Stock Type
Genflow Biosciences Plc GENF London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-0.10 -4.26% 2.25 15:54:46
Open Price Low Price High Price Close Price Previous Close
2.35 2.25 2.35 2.25 2.35
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 05/12/2022 16:52 by moneymunch
LongevityTech.fund II launches – now accepting new investors

August 22, 2022

After successful conclusion of LongevityTech.fund, the second fund is now open for business.

LongevityTech.fund has started accepting new investors for its second fund – Longevitytech.fund II; the first fund concluded with over 40+ investments, including one exit and one IPO – Genflow Bio – placing Longevitytech.fund firmly in the world’s top 5 most active longevity investors.

Longevity.Technology: The fund investments fall into broad longevity categories – therapeutics and the enabling platform technologies, biomarker discovery and diagnostics, including companion diagnostics; investments also include preventative and regenerative modalities and industry accelerators. The impressive portfolio includes BrainKey, Mitrix, Pano Therapeutics, Genflow Biosciences, SENISCA, Gerostate Alpha, NOVOS and Occuity. [A full list appears at the end of this article.]

The fund aims to support and capture the innovation wave through seed, pre-seed and Series A stage investments.

Longevitytech.fund II will be managed by the same team led by Petr Sramek as the first fund, with newly-appointed experienced Jyothi Devakumar, PhD, as the second Managing Partner focused on science. The US-based fund operated from the firm’s Palo Alto, California office.

“The science and industry of longevity is experiencing exponential growth, and we expect massive hype after 2025 when we plan to nurture and gradually exit our portfolio companies,” said Petr Sramek. “Because longevity solutions bring real value to the global population, it will gradually become one of the largest and most impactful industries.”

The fund will start accepting new commitments from investors this week and targets the first closing of the fund in October 2022 with a target fund size of $50 million. Ongoing commitments will be accepted through the beginning of 2023 with a maximum fund size of $100 million.

https://longevity.technology/news/longevitytech-fund-ii-launches-now-accepting-new-investors/amp/

Posted at 28/11/2022 15:04 by moneymunch
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.

 

But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only a few months ago, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that the mega-tech startup would team up with or outright buy Genflow Biosciences, launching its extremely undervalued share price to match, or exceed, its peer group.

Consider that on mere rumors of acquisition for their LIDAR IP, Microvision’s (MVIS) share price exploded almost 300% in less than 2 weeks last year.

Now imagine the sudden news that a Bezo’s backed company set on discovering the formula for immortality is acquiring or partnering with a little-known European biotech start-up with a share price of only 2p

 

News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another. 

https://clearcapitalmarkets.co.uk/biotech-opinion-joe-neighbour/?gclid=EAIaIQobChMInZjjq4TP-wIVhLTtCh3iWQGBEAAYASAAEgIBGfD_BwE

Your Recent History
LSE
GENF
Genflow Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 21:31:34